Countries South Korea
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has received the EcoVadis...
January 30, 2026 | News
SK bioscience announced the initiation of a global Phase 1/2 clinical trial in Australia for GBP511, a vaccine candidate targeting the sarbecovirus subgenu...
January 30, 2026 | News
Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease ...
January 29, 2026 | News
SK bioscience announced that it is advancing the development of a Zaire ebolavirus vaccine under a new collaboration supported by the Coalition for Epidemi...
January 23, 2026 | News
Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion Maintained momentum through consistent ...
January 22, 2026 | Company results
Alteogen Inc. (KOSDAQ: 196170) announced that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK...
January 21, 2026 | News
GCCL, a leading South Korea-based provider of clinical trial sample analysis, and OPIS, a global full-service contract research organization (CR...
January 19, 2026 | News
Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Sam...
January 13, 2026 | News
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ® BYOOVIZ becomes the fourth biosimila...
January 05, 2026 | News
TempraMed Technologies Ltd, a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announc...
January 05, 2026 | News
KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value ti...
January 01, 2026 | News
Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on co...
December 29, 2025 | News
SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (incl...
December 25, 2025 | News
Phase 2 IND submission targeted for the second half of 2026- Demonstrating the competitiveness of GC Biopharma's mRNA platform GC Biopharma (...
December 24, 2025 | News
Most Read
Bio Jobs
News
Editor Picks